These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 18075281)
41. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058 [TBL] [Abstract][Full Text] [Related]
42. A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma. Opsahl EM; Brauckhoff M; Schlichting E; Helset K; Svartberg J; Brauckhoff K; Mæhle L; Engebretsen LF; Sigstad E; Grøholt KK; Akslen LA; Jørgensen LH; Varhaug JE; Bjøro T Thyroid; 2016 Sep; 26(9):1225-38. PubMed ID: 27400880 [TBL] [Abstract][Full Text] [Related]
43. Regulation of proliferation and apoptosis in sporadic and hereditary medullary thyroid carcinomas and their putative precursor lesions. Hinze R; Gimm O; Taubert H; Bauer G; Dralle H; Holzhausen HJ; Rath FW Virchows Arch; 2000 Sep; 437(3):256-63. PubMed ID: 11037345 [TBL] [Abstract][Full Text] [Related]
44. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111 [TBL] [Abstract][Full Text] [Related]
46. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma. Dadu R; Hu MN; Grubbs EG; Gagel RF Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392 [TBL] [Abstract][Full Text] [Related]
47. Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. Szinnai G; Meier C; Komminoth P; Zumsteg UW Pediatrics; 2003 Feb; 111(2):E132-9. PubMed ID: 12563086 [TBL] [Abstract][Full Text] [Related]
48. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Arthan D; Hong SK; Park JI Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039 [TBL] [Abstract][Full Text] [Related]
49. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Eng C; Mulligan LM; Healey CS; Houghton C; Frilling A; Raue F; Thomas GA; Ponder BA Cancer Res; 1996 May; 56(9):2167-70. PubMed ID: 8616867 [TBL] [Abstract][Full Text] [Related]
50. Precision Targeted Therapy with BLU-667 for Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135 [TBL] [Abstract][Full Text] [Related]
51. [The RET gene in thyroid pathology]. Michiels FM; Billaud M Arch Anat Cytol Pathol; 1998; 46(1-2):19-30. PubMed ID: 9754357 [TBL] [Abstract][Full Text] [Related]
52. Medullary thyroid carcinoma and multiple endocrine neoplasia type 2. Takami H Endocr Pathol; 2003; 14(2):123-31. PubMed ID: 12858002 [TBL] [Abstract][Full Text] [Related]
53. Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer. Ferrari SM; La Motta C; Sartini S; Baldini E; Materazzi G; Politti U; Ruffilli I; Ulisse S; Miccoli P; Antonelli A; Fallahi P Mini Rev Med Chem; 2016; 16(2):86-93. PubMed ID: 26471970 [TBL] [Abstract][Full Text] [Related]
54. Distribution of RET Mutations and Evaluation of Treatment Approaches in Hereditary Medullary Thyroid Carcinoma in Turkey. Aydoğan Bİ; Yüksel B; Tuna MM; Navdar Başaran M; Akkurt Kocaeli A; Ertörer ME; Aydın K; Güldiken S; Şimşek Y; Cihan Karaca Z; Yılmaz M; Aktürk M; Anaforoğlu İ; Kebapçı N; Duran C; Taşlıpınar A; Kulaksızoğlu M; Gürsoy A; Dağdelen S; Erdoğan MF J Clin Res Pediatr Endocrinol; 2016 Mar; 8(1):13-20. PubMed ID: 26758973 [TBL] [Abstract][Full Text] [Related]
55. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Marsh DJ; Mulligan LM; Eng C Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949 [TBL] [Abstract][Full Text] [Related]
56. [The treatment of medullary thyroid cancer]. Fujita T; Fujimori M Gan To Kagaku Ryoho; 2009 Oct; 36(10):1627-31. PubMed ID: 19838021 [TBL] [Abstract][Full Text] [Related]
57. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma. Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802 [TBL] [Abstract][Full Text] [Related]
58. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. Romei C; Elisei R; Pinchera A; Ceccherini I; Molinaro E; Mancusi F; Martino E; Romeo G; Pacini F J Clin Endocrinol Metab; 1996 Apr; 81(4):1619-22. PubMed ID: 8636377 [TBL] [Abstract][Full Text] [Related]
59. Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. Ning L; Jaskula-Sztul R; Kunnimalaiyaan M; Chen H Ann Surg Oncol; 2008 Sep; 15(9):2600-5. PubMed ID: 18563491 [TBL] [Abstract][Full Text] [Related]
60. [Somatic ret proto-oncogene mutations in sporadic C-cell carcinoma of the thyroid gland]. Frilling A; Bockhorn M; Kalinin V; Liedke M; Kaun M; Broelsch CE Chirurg; 1997 Aug; 68(8):789-93. PubMed ID: 9377989 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]